Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -53,242 | -58,361 | -48,654 | -23,896 | -14,752 |
| Depreciation Amortization | 1,508 | 1,444 | 1,048 | 577 | 244 |
| Accounts receivable | 1,916 | 3,021 | -6,485 | -416 | 14 |
| Other Working Capital | 1,468 | 12,240 | 8,532 | 20,589 | 20,299 |
| Other Operating Activity | 2,964 | 1,508 | 10,185 | 3,000 | 1,274 |
| Operating Cash Flow | $-45,386 | $-40,148 | $-35,374 | $-148 | $7,080 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -647 | -1,461 | -1,160 | -2,365 | -365 |
| Investing Cash Flow | $-647 | $-1,461 | $-1,160 | $-2,365 | $-365 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 61,823 | 45,358 | 2,570 | 56,003 | 18,343 |
| Financing Cash Flow | $61,823 | $45,358 | $2,570 | $56,003 | $18,343 |
| Beginning Cash Position | 67,465 | 63,716 | 97,679 | 44,189 | 19,132 |
| End Cash Position | 83,256 | 67,465 | 63,716 | 97,679 | 44,189 |
| Net Cash Flow | $15,791 | $3,749 | $-33,963 | $53,490 | $25,057 |
| Free Cash Flow | |||||
| Operating Cash Flow | -45,386 | -40,148 | -35,374 | -148 | 7,080 |
| Capital Expenditure | -647 | -1,461 | -1,160 | -2,365 | -365 |
| Free Cash Flow | -46,032 | -41,609 | -36,534 | -2,513 | 6,715 |